Recursion Pharmaceuticals Appoints New Chief Medical Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 16 2023
0mins
Should l Buy RXRX?
Source: globenewswire
Recursion Pharmaceuticals Inc. shares fell by 6.67% as the stock crossed below its 5-day SMA, reflecting investor caution following the announcement of a new Chief Medical Officer.
The company appointed Vicki Goodman as Chief Medical Officer, effective April 6, 2026, succeeding David Mauro. Goodman brings over 20 years of oncology drug development experience, having previously served as CMO at Mural Oncology. Following this executive change, Recursion's shares dropped by 1.86%, indicating market uncertainty regarding the new CMO's impact and investors' cautious outlook on the company's strategic direction. Despite this transition, Recursion aims to extend its cash runway into early 2028 while enhancing operational efficiency.
The appointment of Goodman may affect short-term market confidence, but the long-term strategy remains focused on innovative drug development. Investors will be watching closely to see how her extensive experience in oncology will influence Recursion's future projects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RXRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RXRX
Wall Street analysts forecast RXRX stock price to rise
6 Analyst Rating
2 Buy
4 Hold
0 Sell
Moderate Buy
Current: 3.150
Low
5.00
Averages
7.75
High
11.00
Current: 3.150
Low
5.00
Averages
7.75
High
11.00
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Recursion Pharmaceuticals Stock Decline Analysis
- Stock Performance: Recursion Pharmaceuticals (RXRX) closed at $2.94, down 6.67% from the previous session, significantly underperforming the S&P 500's 1.67% decline, indicating weakness in market sentiment towards the company.
- Monthly Decline: The stock has fallen 16.45% over the past month, greatly exceeding the Medical sector's 7.36% and the S&P 500's 6.15% losses, reflecting investor concerns regarding its future profitability.
- Earnings Expectations: The upcoming earnings report is expected to show an EPS of -$0.27, a 46% increase from the prior year, with revenue projected at $20.73 million, up 40.65% year-over-year, indicating potential business growth.
- Analyst Ratings: Currently holding a Zacks Rank of #3 (Hold), Recursion's EPS estimate has increased by 9.98% in the last 30 days, suggesting analysts' growing confidence in the company's short-term performance, despite its industry ranking being in the bottom 40% of over 250 sectors.
See More
Recursion Appoints New Chief Medical Officer
- Executive Change: Recursion announced the appointment of Vicki Goodman as Chief Medical Officer, effective April 6, 2026, succeeding David Mauro; Goodman brings over 20 years of oncology drug development experience, having most recently served as CMO at Mural Oncology, where she advanced its pipeline.
- Extensive Industry Background: Goodman has held senior oncology roles at Merck and Bristol Myers Squibb, leading the development of key drugs such as Keytruda, Opdivo, and Yervoy, showcasing her deep expertise in cancer therapeutics.
- Market Reaction: Following the announcement of this executive change, Recursion's shares fell by 1.86%, indicating market uncertainty regarding the new CMO's impact and investors' cautious outlook on the company's strategic direction.
- Future Outlook: Recursion expects to extend its cash runway into early 2028 while enhancing operational efficiency; although the executive transition may affect short-term market confidence, the long-term strategy remains focused on innovative drug development.
See More
RECURSION PHARMACEUTICALS INC NAMES VICKI GOODMAN AS CHIEF MEDICAL OFFICER, STARTING APRIL 6, 2026
- New Appointment: Recursion Pharmaceuticals has appointed Vicki Goodman as their new Chief Medical Officer.
- Effective Date: The appointment is effective from April 6, 2026.
See More
AI Stocks Face Revaluation and Opportunities Ahead
- Market Revaluation: Recently, AI stocks have faced a revaluation, with Microsoft shares down over 20% from last year's peak and Oracle's shares halved due to concerns over AI infrastructure spending, reflecting skepticism about the technology's value.
- Investor Psychological Cycle: AI is currently in the 'trough of disillusionment' phase, and while performance is poor in the short term, history shows this stage often precedes a recovery, suggesting investors should view this as a long-term buying opportunity.
- Oracle's Growth Potential: Oracle expects its AI infrastructure revenue to grow from $18 billion this year to $144 billion by 2030, nearly three times its total revenue from the last fiscal year, indicating significant potential in its shift to the AI market.
- Google Cloud's Competitive Edge: Google's cloud computing segment is its fastest-growing business, and while AI accounts for only 15% of its revenue, its enterprise-focused capabilities are rapidly increasing market share, indicating strong future growth potential.
See More
AI Stocks Face Challenges and Opportunities Amid Market Correction
- Market Correction Impact: The overall market has faced challenges in recent weeks, with AI stocks like Microsoft and Oracle seeing declines of over 20% and 50%, respectively, indicating a reevaluation of AI technology's value and leading to a repricing of related companies.
- Disillusionment Cycle Analysis: According to Gartner's Hype Cycle, AI is currently in the 'trough of disillusionment,' where, despite future potential, the current reality has not met initial high expectations, causing many companies to struggle.
- Investment Opportunity Identification: Despite short-term challenges, investors should view this as a long-term buying opportunity, particularly as Oracle anticipates its AI infrastructure revenue to grow from $18 billion this year to $144 billion by 2030, showcasing strong growth potential.
- Market Leader Outlook: Google's cloud computing division is excelling in the AI space; while AI is not its largest business, the rapidly growing cloud segment is expected to benefit from the upcoming 'slope of enlightenment,' providing new growth momentum for the company.
See More
AI Drug Discovery Efficiency Boost
- Drug Discovery Efficiency: Recursion Pharmaceuticals synthesizes an average of 330 compounds in 17 months, significantly outperforming the industry average of 2,500 compounds over 42 months, thereby accelerating new drug development and enhancing market competitiveness.
- Substantial Partnership Revenue: Recursion has secured $213 million in fees from collaborations with Roche and Genentech, highlighting the commercial value of its proprietary whole-genome CRISPR knockout maps, which further solidifies its leadership in the biopharmaceutical sector.
- Tempus AI's Market Potential: Tempus AI's trailing revenue reached $1.27 billion, growing approximately 30% annually, with its unique clinical data library and AI analytics positioning it as a key player in precision medicine, attracting numerous pharmaceutical partnerships.
- Future Growth Expectations: Analysts project nearly 30% annual revenue growth for Tempus AI over the next three years, with consensus price targets implying over 60% upside for the stock in the next year, reflecting strong market confidence in its long-term growth potential.
See More
Recursion Pharmaceuticals Stock Decline Analysis
- Stock Performance: Recursion Pharmaceuticals (RXRX) closed at $2.94, down 6.67% from the previous session, significantly underperforming the S&P 500's 1.67% decline, indicating weakness in market sentiment towards the company.
- Monthly Decline: The stock has fallen 16.45% over the past month, greatly exceeding the Medical sector's 7.36% and the S&P 500's 6.15% losses, reflecting investor concerns regarding its future profitability.
- Earnings Expectations: The upcoming earnings report is expected to show an EPS of -$0.27, a 46% increase from the prior year, with revenue projected at $20.73 million, up 40.65% year-over-year, indicating potential business growth.
- Analyst Ratings: Currently holding a Zacks Rank of #3 (Hold), Recursion's EPS estimate has increased by 9.98% in the last 30 days, suggesting analysts' growing confidence in the company's short-term performance, despite its industry ranking being in the bottom 40% of over 250 sectors.
See More
Recursion Appoints New Chief Medical Officer
- Executive Change: Recursion announced the appointment of Vicki Goodman as Chief Medical Officer, effective April 6, 2026, succeeding David Mauro; Goodman brings over 20 years of oncology drug development experience, having most recently served as CMO at Mural Oncology, where she advanced its pipeline.
- Extensive Industry Background: Goodman has held senior oncology roles at Merck and Bristol Myers Squibb, leading the development of key drugs such as Keytruda, Opdivo, and Yervoy, showcasing her deep expertise in cancer therapeutics.
- Market Reaction: Following the announcement of this executive change, Recursion's shares fell by 1.86%, indicating market uncertainty regarding the new CMO's impact and investors' cautious outlook on the company's strategic direction.
- Future Outlook: Recursion expects to extend its cash runway into early 2028 while enhancing operational efficiency; although the executive transition may affect short-term market confidence, the long-term strategy remains focused on innovative drug development.
See More
RECURSION PHARMACEUTICALS INC NAMES VICKI GOODMAN AS CHIEF MEDICAL OFFICER, STARTING APRIL 6, 2026
- New Appointment: Recursion Pharmaceuticals has appointed Vicki Goodman as their new Chief Medical Officer.
- Effective Date: The appointment is effective from April 6, 2026.
See More
AI Stocks Face Revaluation and Opportunities Ahead
- Market Revaluation: Recently, AI stocks have faced a revaluation, with Microsoft shares down over 20% from last year's peak and Oracle's shares halved due to concerns over AI infrastructure spending, reflecting skepticism about the technology's value.
- Investor Psychological Cycle: AI is currently in the 'trough of disillusionment' phase, and while performance is poor in the short term, history shows this stage often precedes a recovery, suggesting investors should view this as a long-term buying opportunity.
- Oracle's Growth Potential: Oracle expects its AI infrastructure revenue to grow from $18 billion this year to $144 billion by 2030, nearly three times its total revenue from the last fiscal year, indicating significant potential in its shift to the AI market.
- Google Cloud's Competitive Edge: Google's cloud computing segment is its fastest-growing business, and while AI accounts for only 15% of its revenue, its enterprise-focused capabilities are rapidly increasing market share, indicating strong future growth potential.
See More
AI Stocks Face Challenges and Opportunities Amid Market Correction
- Market Correction Impact: The overall market has faced challenges in recent weeks, with AI stocks like Microsoft and Oracle seeing declines of over 20% and 50%, respectively, indicating a reevaluation of AI technology's value and leading to a repricing of related companies.
- Disillusionment Cycle Analysis: According to Gartner's Hype Cycle, AI is currently in the 'trough of disillusionment,' where, despite future potential, the current reality has not met initial high expectations, causing many companies to struggle.
- Investment Opportunity Identification: Despite short-term challenges, investors should view this as a long-term buying opportunity, particularly as Oracle anticipates its AI infrastructure revenue to grow from $18 billion this year to $144 billion by 2030, showcasing strong growth potential.
- Market Leader Outlook: Google's cloud computing division is excelling in the AI space; while AI is not its largest business, the rapidly growing cloud segment is expected to benefit from the upcoming 'slope of enlightenment,' providing new growth momentum for the company.
See More
AI Drug Discovery Efficiency Boost
- Drug Discovery Efficiency: Recursion Pharmaceuticals synthesizes an average of 330 compounds in 17 months, significantly outperforming the industry average of 2,500 compounds over 42 months, thereby accelerating new drug development and enhancing market competitiveness.
- Substantial Partnership Revenue: Recursion has secured $213 million in fees from collaborations with Roche and Genentech, highlighting the commercial value of its proprietary whole-genome CRISPR knockout maps, which further solidifies its leadership in the biopharmaceutical sector.
- Tempus AI's Market Potential: Tempus AI's trailing revenue reached $1.27 billion, growing approximately 30% annually, with its unique clinical data library and AI analytics positioning it as a key player in precision medicine, attracting numerous pharmaceutical partnerships.
- Future Growth Expectations: Analysts project nearly 30% annual revenue growth for Tempus AI over the next three years, with consensus price targets implying over 60% upside for the stock in the next year, reflecting strong market confidence in its long-term growth potential.
See More
